Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 610-616

  Shitara, Yoshihisa ^a,b,d   Itoh, Tomoo ^c   Sato, Hitoshi ^d   Li, Albert P ^e,f   Sugiyama, Yuichi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY   (Japan)

^e In Vitro Technologies Inc   (United States)

^f Phase 1 Molecular Toxicology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYCLOSPORIN A; ORGANIC ANION TRANSPORTER;

ARTICLE; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; KINETICS; LIVER CELL; LIVER METABOLISM; PRIORITY JOURNAL;

CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; LIVER; MICROSOMES, LIVER; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRIDINES;

EID: 0037310871     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.041921     Document Type: Article

References (39)

1. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, et al. (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159-17163.
2. Charatan F (2001) Bayer decides to withdraw cholesterol lowering drug. Br Med J 323:359.
3. Deseger J-P and Horsmans Y (1996) Clinical pharmacokinetics of 3-hydroxy·3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 31:348-371.
4. Hirayama M, Yoshimura Y, and Moriyasu M (2000) Carrier-mediated uptake of cerivastatin in primary cultured rat hepatocytes. Xenobio Metab Dispos 15:219-225.
5. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
6. Ito K, Iwtsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
7. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res (NY) 17:419-426.
8. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, and Sugiyama Y (2000) Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo [2, 3-B]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)- phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos 28:1238-1243.
9. Komai T, Shigehara E, Tokui T, Ishigami M, Kuroiwa C, and Horiuchi S (1992) Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43:667-670.
10. König J, Cui Y, Nies AT, and Keppler D (2000a) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol 278:G156-G164.
11. König J, Cui Y, Nies AT, and Keppler D (2000b) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161-23168.
12. Kok LD, Siu SS, Fung KP, Tsui SK, Lee CY, and Waye MM (2000) Assignment of liver-specific organic anion transporter (SLC22A7) to human chromosome 6 bands p21.2->p21.1 using radiation hybrids. Cytogenet Cell Genet 88:76-77.
13. Kouzuki H, Suzuki H, Ito K, Ohashi R, and Sugiyama Y (1999a) Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286:1043-1050.
14. Kouzuki H, Suzuki H, Ito K, Ohashi R, and Sugiyama Y (1999b) Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 288:627-634.
15. Kusuhara H and Sugiyama Y (2001) Drug-drug interactions involving the membrane transport process, in Drug-Drug Interactions (Rodrigues AD ed) pp 123-188, Marcel Dekker, New York.
16. Kusuhara H and Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Controlled Release 78:43-54.
17. Lemaire M and Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34:715-718.
18. Li AP, Roque MA, Beck DJ, and Kaminsli DL (1992) Isolation and culturing of hepatocytes from human liver. J Tissue Culture Meth 14:139-146.
19. Li AP, Lu C, Brendt JA, Fackett A, Ruegg CE, and Silber PA (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability and drug-drug interaction potential. Chem-Biol Interact 121:17-35.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randal RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
21. Mizuno N and Sugiyama Y (2002) Drug transporters: their role and importance in new drug selection and development. Drug Metab Pharmacokinet 17:93-108.
22. Moghadasian MH (1999) Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 65:1329-1337.
23. Mück W, Ochmann K, Rohde G, Unger S, and Kuhlmann J (1998) Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53:469-473.
24. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, et al. (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporin-treated kidney transplant recipients. Clin Pharmacol Ther 65:251-261.
25. Mück W (2000) Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 39:99-116.
26. Mueck W, Frey R, Boix O, and Voith B (2001) Gemfibrozil/cerivastatin interaction (Abstract). AAPS PharmSci 3 (Suppl):3566
27. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, and Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867.
28. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
29. Ong CE, Coulter S, Birkett DJ, Bhasker CR, and Miners JO (2000) The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 50:573-580.
30. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, and Baillie TA (2002) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
31. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, and Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
32. Regazzi MB, Campana IC, Raddato V, Lesi C, Perani G, Gavazzi A, and Vigano M (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732-2734.
33. Sasaki M, Suzuki H, Ito K, Abe T, and Sugiyama Y (2002) Transcellular transport of organic anions across double-transfected MDCKII cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497-6503.
34. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat Oatp1[Slc21a1)- and Oatp2(Slc21a5)-mediated transport. Pharm Res (NY) 19:147-153.
35. Sugiyama Y, Kato Y, and Ito K (2002) Quantitative prediction: metabolism, transport in the liver, in Preclinical and Clinical Evaluation of Drug-Drug Interactions (Li AP and Sugiyama Y eds) pp 108-124, ISE Press, Baltimore.
36. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, and Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260.
37. Todd PA and Ward A (1988) Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 36:314-339.
38. Ueda K, Kato Y, Komatsu K, and Sugiyama Y (2001) Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 297:1036-1043.
39. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.